Results 1 - 10 of 78 : 1 2 3 4 5 6 7 8 Next
Don't Make a Million-Dollar Mistake
It's not too late to make your million.
PDL BioPharma's Partnership Makes Sense
Bristol-Myers assumes some of the risk of developing a drug for bone marrow cancer.
Health-Care Stocks the All-Stars Prescribe
These CAPS picks could be just what the doctor ordered.
When Breaking Up Isn't Hard to Do
PDL BioPharma and Enzon look to spin off parts of their business.
Despite his tough talk, Icahn will likely complete a buyout of ImClone.
Seattle Genetics Has What Others Want
Out-licensing its platform technology could mean big bucks.
Live From Bio: Activist Investors
When activist investors board your company's ship.
The interim CEO's departure is only the latest executive exit.
The activist investor officially launches his bid to usurp Biogen's board of directors.
The pharmaceutical's assets are worth more than Wall Street thinks.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK